DOWNLOAD REQUEST - FCF LIFE SCIENCES RESEARCH SERIES
FCF Life Sciences engages in research on recent financing trends in the Life Sciences sector, i.e. biotechnology, pharma and med-tech. FCF primarily focuses on the latest activities in the equity capital markets: Venture Capital, Initial Public Offerings (IPO) and Equity Valuations.
The findings are regularly published in:
NEWS & PRESS
Life Sciences Venture Capital Monitor – Europe 07/2022 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 07/2022”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences
Venture Capital Sentiment Tracker – July 2022
July 2022: Biotechnology Medical Technology Health Technology Funding Volume (€m) 0 Trend Funding Volume (€m) 0 Trend Funding Volume (€m) 0 Trend Biotechnology Funding Volume (€m) 0 Trend Medical Technology Funding Volume (€m) 0 Trend
Longevity on the rise – Constant growth in the US and its arrival in Europe
The significant growth of transaction volumes and the number of deals closed from 2017 to 2021 confirms the increasing importance of longevity in the US and Europe. For both markets, the number of deals almost
FCF Biotech Venture Capital Monitor – USA 06/2022 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 06/2022”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
Funding for Genomics exceeds all other subsectors in the ‘OMX-space
Genomics represents the most crucial pillar in the ‘OMX-space and is the largest subsector in the US and Europe (EUR 13.3bn vs. EUR 1.8bn). The second and third largest subsectors are microbiomics and proteomics for
